|By Business Wire||
|April 8, 2014 09:13 AM EDT||
Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that Tal Wenderow, Co-founder and EVP of Product & Business Development of Corindus, will present at the upcoming Design of Medical Device Conference. The conference is being held April 7-10 at The Commons Hotel & McNamara Alumni Center, on the University of Minnesota Twin Cities Campus in Minneapolis, Minn.
CorPath is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. The system enables precisely controlled, robotic-assisted angioplasties while the physician is seated in a lead-lined interventional cockpit protected from radiation exposure. CorPath allows the cardiologist to advance stents and guidewires millimeter-by-millimeter using joysticks and touchscreen controls.
Wenderow’s presentation, titled “Robotic Stent Placement during Coronary Intervention,” will review how robotic assistance has the potential to revolutionize vascular interventions by enabling procedures to be completed with robotic precision, which may improve outcomes. The discussion aims to provide state of the art perspective from leaders in the robotic industry. This session will take place on April 9 beginning at 2:00 p.m. CST.
“As a leader in the medical robotics space, we are pleased to have the opportunity to participate in this conference and share our insight and findings that point to an increasing need for robotics during coronary intervention,” said Tal Wenderow.
CorPath was highlighted at ACC 2014, where a live case was presented for the attendees. During the case, CorPath’s robotic precision was highlighted as the operator demonstrated the ability to move the stent in one millimeter increments, placing it where he, and the case panel, felt it was optimal for patient care.
In addition to Tal Wenderow’s talk, the catheter robotics session will feature speakers from other companies in the industry as well as academics from nationally recognized institutions.
To learn more about this conference, visit Design of Medical Devices Conference site.
About Corindus Vascular Robotics
Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with a “One Stent Promise,” offering a $1,000 credit to hospitals that use two or more stents per lesion in PCI procedures performed with the CorPath System. For additional information, visit www.corindus.com, and follow @CorindusInc.
Jul. 28, 2016 10:00 PM EDT Reads: 2,094
Jul. 28, 2016 10:00 PM EDT Reads: 1,714
Jul. 28, 2016 10:00 PM EDT Reads: 1,436
Jul. 28, 2016 09:00 PM EDT Reads: 2,701
Jul. 28, 2016 07:15 PM EDT Reads: 1,228
Jul. 28, 2016 07:15 PM EDT Reads: 368
Jul. 28, 2016 06:45 PM EDT Reads: 1,635
Jul. 28, 2016 06:30 PM EDT Reads: 1,660
Jul. 28, 2016 06:00 PM EDT Reads: 955
Jul. 28, 2016 05:30 PM EDT Reads: 1,864
Jul. 28, 2016 05:30 PM EDT Reads: 2,214
Jul. 28, 2016 05:00 PM EDT Reads: 432
Jul. 28, 2016 04:30 PM EDT Reads: 916
Jul. 28, 2016 04:30 PM EDT Reads: 1,191
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
Jul. 28, 2016 04:15 PM EDT Reads: 376